TW467912B - 2-{3-[4-(2-T-Butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol fumarate - Google Patents
2-{3-[4-(2-T-Butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol fumarate Download PDFInfo
- Publication number
- TW467912B TW467912B TW087113230A TW87113230A TW467912B TW 467912 B TW467912 B TW 467912B TW 087113230 A TW087113230 A TW 087113230A TW 87113230 A TW87113230 A TW 87113230A TW 467912 B TW467912 B TW 467912B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- butyl
- fumarate
- pyrimidinol
- dopamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Description
4 6 7 9 1 2 A7 -_B7五、發明説明(1 ) 本發明係關於2-{3-[4-(2-第三-丁基-6-三氟甲基-4-鳴设# < - .1. 六氫吡井基]两硫基}-4-嘧啶醇之反丁缔二酸鹽,刀4 〜 包含此 化合物之醫藥組合物。此化合物具有價値之治療性質 特別可用於治療會回應多巴胺D3配位體之病症。 ’具 W0 96/0?519係描述該化合物 呈 下式 自由態驗形式’其具有
N
N
經濟部中央標準局員X消贽合作社印製 其同樣可用於治療會回應多巴胺D3配位體之病症 並未揭示此化合物之鹽。 目前已令人驚訝地發現此化合物與反丁浠二酸 鹽,具有特殊優點。 因此,本發明係關於2_{3-[4-(2-第三-丁基-6-三氣甲基 淀基)-1-六氳峨β井基]丙硫基密喊醇之反丁缔 包含此化合物之醫.藥組合物。 本發明亦關於該反丁烯二酸鹽之互變異構形 八(ρ比酿| 結構)以友溶劑合物與水合物。 此反丁烯二酸鹽對於〇3受體具有極良好5親和力與高選擇 性,意即其爲一種選擇性多巴胺〇3受體之配位體,其係區 域選擇性地作用在邊緣系統上。 但是, 之酸加成 醆鹽,及 -4 - ^紙張人度適用中國國家標準(C:NS ) Λ4規格(210χ297公釐) (請先閱讀背面之注$項再填{5?本耳』
A7 4 6 7 9 12 —一__ B7 - | . || ______ 五、發明説明(2 )
其具有選擇性冯02/1^03爲120 (參閲W0 96/02519)。因此, 此化合物可用於治療會回應多巴胺D3配位體之病症,例如 ’用以治療中樞神經系統之病症,特別是精神分裂症、抑 鬱' 神經官能症及精神病。其另外可用於治療睡眠失調與 惡心,及作爲抗組織胺藥。此等物質之溶解度試驗,與自 由態驗比較’顯示此鹽在水中之實質上較高溶解度。因此 ’當此物質以口服方式及特別是以非經腸方式投藥時,吸 收係顯著地被加強D 再者,此反丁烯二酸鹽比自由態鹼更可溶於極性溶劑譬 如C1 -仁6·烷醇中。由於此經改變之溶解度特性,故其亦可 較簡單地使用生理學上無法接受之溶劑純化。 此自由態鹼可藉WO 96/02519中所述之一般方法,較佳係 藉方法(ii)製備。其反丁晞二酸鹽可經由使自由態鹼與反丁 埽二酸,在適當溶劑中反應而獲得,該溶劑譬如Ci_Cp故 醇’特別是曱醇、乙醇、正-丙醇 '異丙醇及正-丁醇,水 與該醇類其中一種之混合物,或酯類譬如醋酸乙酯。通常 係使用高溫,因此所需要之反丁烯二酸鹽會於冷卻時結晶 析出’並可以直接方式分離。反丁烯二酸通常係以等莫耳 量或以至高約10%之稍微過量添加》依此方式製成之反丁 埽二酸鹽,已具有高純度。其亦可另外經由在適當溶劑中 攪拌,或自其再結晶而純化,該溶劑例如水,上述挽醇之 一,酯類或其混合物。 ~ 爲治療上述病症,係將此新穎化合物以口服方式或以非 經腸方式(皮下、靜脈内、肌内、腹膜腔内),以習用方式 - .—- ___^_____ 本紙張尺度適州中國國家操準( CNS ) Λ4^#· ( 210 /297^¾ ) ~~' ---- ---------—ο裝! •^請先聞讀背面之注項再填寫本頁} -5 J. 經濟部中央榡率局货工消费合作社印" Α7 Β7 467912 五、發明説明(3) 投藥。口服投藥係爲較佳的。 ------——— (請先閱讀背面之注意事項再填寫本頁) 其劑(量係依病人之年齡、症狀及體重,以及投藥模式而 定。通常’活性物質之日服劑量係爲每—病人約1〇至1〇⑻ 毫克,且每天以口服投藥,及每一病人約1至5〇〇毫克,且 每天以非經腸投藥。 本發明亦關於包含此新穎化合物之醫藥組合物。此等組 合物係呈一般固體或液體醫藥形式,例如作成未經塗覆或 經(薄膜)塗覆之片劑、膠囊、粉末、顆粒、栓劑、溶液或 噴霧劑。供此項目的使用之活性物質,可以習用醫藥助劑 加工處理’譬如片劑黏合劑、膨鬆化劑、防腐劑、片劑崩 解劑、流動調節劑、增塑劑、潤濕劑、分散劑、乳化劑、 溶劑、減緩釋出劑、抗氧化劑及/或推進劑氣體(參閲 H Sucker 等人,Pharmazeutische Technologie,Thieme-Verlag, Stuttgart, 1978)。依此方式獲得之投藥形式,通常含有1至99重量% 活性物質。 下述實例係用以説明本發明,而非,限制之。 實例1 經濟部中次標準局員工消费合作社印製 2·{3-[4-(2-第三-丁基_6_三氟甲基冰嘧啶基)·ι·六氫吡畊基]丙硫 基Η-嘧啶醇之反丁烯二酸鹽之製備 弟二丁基”4-經基-6-三氣甲基喊症(1) 此起始物質係爲文獻上已知。 在已溶解於200毫升乙醇中之50克(0.37莫耳)2,2-二甲基丙 脒鹽酸鹽中,於室溫下添加66,6克(0,37莫耳)甲醇鈉(30%濃 度,在甲醇中),及又30分鐘後,添加52克(0.28莫耳)三氟 _____________ - 6 - ______ 本紙張尺度適ffl中國國家標準(CNS ) Λ4规格(2]0Χ297公釐) 4 經濟部中夾標準局員工消贽合作社印製 A7 B7 五、發明説明(4) 醋酸乙酯。在回流17小時後,在減壓下移除溶劑,將200 毫升求加入殘留物中.,並於酸化至pH値4之後,藉過濾分 離已結晶之固體。 產量:62.2克 (理論値之98% ) C9hiiF3N2° (MW 220) 炫點 187-188Ό 第三-丁基-4-氣三氟甲基嘧啶(2) 首先將86.5毫升二氯化亞硫醯,然後將8毫升DMF逐滴添 加至60克(0.27莫耳)2-第三-丁基-4-羥基-6-三氟甲基嘧啶在 800毫升二氣甲烷中之溶液内,接著使混合物回流。在減 壓下移除揮發性成份,使殘留物溶於1〇〇毫升二氯甲烷中 ,以飽和NaHC〇3溶液使pH値調整至7,及藉萃取處理後, 獲得67克(96% )透明油。 產量67克 (理論値之96% )
CgHj QF3N2 (MW 239) 2-第三-丁基-4-(1-六氫吡啡基)_6_三氟甲基嘧啶(3) 將60克(0.25莫耳)上述氣基嘧啶在200毫升乙醇中之溶液 ,逐滴添加至129克(1.5莫耳)六氫吡畊在500毫升乙醇中之 煮沸溶液内,歷經2小時期間,然後將混合物再煮彿6小時 。在反應已无成後,於減壓下移除溶劑,並將殘留物與2 升水混合。產物於冷卻時結晶,然後以抽氣過滤。 產量:56克 (理論値之77% ) C13H19C1F3N4(MW288)熔點 78-80*C 、 1H-NMR (250 MHz’CDa3) : s = 1.3 (s, 9H) ; 1.8 (s, 1H); 3.0 (m, 4H) ; 4.7 (m, 4H) ; 6.6 (s, 1H) ppm 〇 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210 X 公楚) (請先閲讀背面之注意事項再填寫本頁)
A7 B7 46791 2 五、發明説明(5) 2-第三-丁基-4-[4-(3-氣丙基)-1-六氫吡啡基]-6-三氟甲基-嘧啶(4) 將已溶解於130毫升THF中之43.2克(0.15莫耳)上述六氫吡 畊,逐滴添加至35.1克(0.22莫耳)1-溴-3-氯丙烷與16.0克 (0.16莫耳)三乙胺在90毫升THF中之煮沸混合物内,並將混 合物在此溫度下攪拌8小時《於冷卻至4°C後,濾除無機鹽 ,在減壓下使THF相濃縮,並使殘留物自異丙醇再結晶。 產量:32.1克 (理論値之01% ) C16H24C1F3N4 (MW 365) 熔點 83-84X: 1H-NMR(250MHz,CDC13) : ά = 1.3 (s, 9Η) ; 1.9 (q, 2H); 2.5 (m,6H) ; 3.7 (t,2H) ; 3.8 (m, 4H) ; 6.6 (s,1H) ppm。 2-{3-[4-(2-第三-丁基-6-三氟甲基斗嘧啶基)-1-六氫吡畊基]丙硫 基}-4-嘧啶醇(5) 將8.4克(0.066莫耳)硫尿嘧啶、1.6克(0.066莫耳)氫氧化鋰 及1,0克(0.066莫耳)碘化鈉,溶解於200毫升DMF中,並加熱 至100°C。在此溫度下,添加已溶解於50毫升DMF中之20.1 克(0.055莫耳)上述氯鹼,接著在l〇〇°C下攪拌30分鐘。然後 ,添加300毫升氯化鈉溶液,並將混合物以200毫升醋酸乙 酯萃取兩次。有機相以硫酸鈉乾燥,並在過濾後,於減壓 下蒸發。 殘留物藉管柱層析純化(矽膠,二氯甲烷與1-4%甲醇)。 產量:18克 (理論値之72% ) v
C2〇H27F3N6OS (MW457)熔點 138-140°C 1H-NMR(270MHz,DMSO-d6) : ά = 1.3 (s, 9Η) ; 1.8 (q, 2H); 2.4(m,6H) ; 3.3(t,2H) ; 3.75 (m, 4H) ; 6.1 (d, 2H) ; 7.1 (s, 1H); -----------zAz__ 本紙张尺度埯和中國囤家標jf ( rNS ) Λ4規格(2IOX297公漦) (請先閲讀背面之注意事項再填寫本頁)
4 6 7 9 1 2 A7 _ B7 五、發明説明(6 7.9(2,2H)ppm。 反丁缔1二酸鹽⑼之製備: 將4.56克(0_01莫耳)上述鹼溶解於25毫升熱異丙醇中,並 添加1.16克(0.01莫耳)反丁烯二酸在15毫升異丙醇中之熱溶 液。此物質於冷卻時結晶析出,並將其過濾,形成4.4克標 題化合物,爲無色結晶。 產量:4.4克 (理論値之76% )
C20H27F3N6OSxC4H4〇4 (MW573) 熔點 200-202°C DMSO-d6) : S = 1.3 (s, 9H) ; 1.9 (q, 2H); 2.5(m,6H) ; 3.2(t,2H) ; 3.8 (mbr, 6H) ; 6.2 (d, 2H) ; 6.7(s, 2H); 7.1 (s,1H) ; 7.9(d,2H)。 ------1----- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局貝工消费合作社印絜 -9- 本紙張尺度適用中國國家標準((:NS ) M規格{ 210X 297公釐)
Claims (1)
- 4 6 7 f ?72323〇銳專利申請案 AS 中文申請專利正太(90年4骂 經濟部中央橾準局貝工消費合作社印製 範園 修Ά 禎見 L 一種下式之2-{Η4·(2-第三·丁基:6.-了氣申—m'啶基)-1-六 氫吡井基]丙硫基}_4_嘧啶醇之反丁烯二酸鹽 οκ C义, 、〇• N (CH3) CFj 及其互變異構形式、溶劑合物與水合物。 2. —種用於治療會回應多巴胺。配位體之 合物,其包含根據申請專利範圍第1項之反丁婦二酸 鹽,使用或未使用生理學上可接受之媒劑及/或輔助 物質。 病症之醫藥組 (請先閲讀背面之注意事項再填寫本頁)本紙張尺度適用t國國家榇準(CNS ) Α4規格(210X297公釐) 4 6 7 f ?72323〇銳專利申請案 AS 中文申請專利正太(90年4骂 經濟部中央橾準局貝工消費合作社印製 範園 修Ά 禎見 L 一種下式之2-{Η4·(2-第三·丁基:6.-了氣申—m'啶基)-1-六 氫吡井基]丙硫基}_4_嘧啶醇之反丁烯二酸鹽 οκ C义, 、〇• N (CH3) CFj 及其互變異構形式、溶劑合物與水合物。 2. —種用於治療會回應多巴胺。配位體之 合物,其包含根據申請專利範圍第1項之反丁婦二酸 鹽,使用或未使用生理學上可接受之媒劑及/或輔助 物質。 病症之醫藥組 (請先閲讀背面之注意事項再填寫本頁)本紙張尺度適用t國國家榇準(CNS ) Α4規格(210X297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19735410A DE19735410A1 (de) | 1997-08-14 | 1997-08-14 | 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat |
Publications (1)
Publication Number | Publication Date |
---|---|
TW467912B true TW467912B (en) | 2001-12-11 |
Family
ID=7839072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087113230A TW467912B (en) | 1997-08-14 | 1998-08-12 | 2-{3-[4-(2-T-Butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol fumarate |
Country Status (25)
Country | Link |
---|---|
US (1) | US20010020022A1 (zh) |
EP (2) | EP2272833A1 (zh) |
JP (1) | JP4444492B2 (zh) |
KR (1) | KR100571945B1 (zh) |
CN (1) | CN1267286A (zh) |
AR (1) | AR016605A1 (zh) |
AT (1) | ATE525362T1 (zh) |
AU (1) | AU749575B2 (zh) |
BG (1) | BG104122A (zh) |
BR (1) | BR9811177A (zh) |
CA (1) | CA2301297A1 (zh) |
CO (1) | CO4960663A1 (zh) |
DE (1) | DE19735410A1 (zh) |
ES (1) | ES2374156T3 (zh) |
HU (1) | HUP0003710A3 (zh) |
ID (1) | ID24639A (zh) |
IL (1) | IL134246A (zh) |
NO (1) | NO314935B1 (zh) |
NZ (1) | NZ502675A (zh) |
PL (1) | PL201927B1 (zh) |
SK (1) | SK1182000A3 (zh) |
TR (1) | TR200000406T2 (zh) |
TW (1) | TW467912B (zh) |
WO (1) | WO1999009015A1 (zh) |
ZA (1) | ZA987239B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE402704T1 (de) * | 2000-03-27 | 2008-08-15 | Abbott Gmbh & Co Kg | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
JP4904267B2 (ja) * | 2004-08-09 | 2012-03-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンd3受容体の調節に応答する障害の治療に好適な4−ピペラジニル−ピリミジン化合物 |
CN102887860B (zh) * | 2012-09-29 | 2015-07-01 | 上海泰坦科技有限公司 | 4-氯-6-三氟甲基嘧啶类化合物的制备方法 |
WO2014059265A1 (en) | 2012-10-11 | 2014-04-17 | Southern Research Institute | Urea and amide derivatives of aminoalkylpiperazines and use thereof |
US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
-
1997
- 1997-08-14 DE DE19735410A patent/DE19735410A1/de not_active Withdrawn
-
1998
- 1998-08-12 TW TW087113230A patent/TW467912B/zh not_active IP Right Cessation
- 1998-08-12 AR ARP980103980A patent/AR016605A1/es not_active Application Discontinuation
- 1998-08-13 ZA ZA9807239A patent/ZA987239B/xx unknown
- 1998-08-13 CO CO98046527A patent/CO4960663A1/es unknown
- 1998-08-14 US US09/485,460 patent/US20010020022A1/en not_active Abandoned
- 1998-08-14 CA CA002301297A patent/CA2301297A1/en not_active Abandoned
- 1998-08-14 KR KR1020007001435A patent/KR100571945B1/ko not_active IP Right Cessation
- 1998-08-14 HU HU0003710A patent/HUP0003710A3/hu unknown
- 1998-08-14 PL PL338603A patent/PL201927B1/pl unknown
- 1998-08-14 ES ES98946343T patent/ES2374156T3/es not_active Expired - Lifetime
- 1998-08-14 WO PCT/EP1998/005178 patent/WO1999009015A1/de not_active Application Discontinuation
- 1998-08-14 AT AT98946343T patent/ATE525362T1/de active
- 1998-08-14 SK SK118-2000A patent/SK1182000A3/sk unknown
- 1998-08-14 TR TR2000/00406T patent/TR200000406T2/xx unknown
- 1998-08-14 NZ NZ502675A patent/NZ502675A/en not_active IP Right Cessation
- 1998-08-14 EP EP10179278A patent/EP2272833A1/de not_active Withdrawn
- 1998-08-14 CN CN98808156A patent/CN1267286A/zh active Pending
- 1998-08-14 AU AU93426/98A patent/AU749575B2/en not_active Ceased
- 1998-08-14 JP JP2000509698A patent/JP4444492B2/ja not_active Expired - Lifetime
- 1998-08-14 IL IL13424698A patent/IL134246A/en not_active IP Right Cessation
- 1998-08-14 BR BR9811177-9A patent/BR9811177A/pt not_active IP Right Cessation
- 1998-08-14 EP EP98946343A patent/EP1003728B1/de not_active Expired - Lifetime
- 1998-08-14 ID IDW20000266A patent/ID24639A/id unknown
-
2000
- 2000-02-03 BG BG104122A patent/BG104122A/xx unknown
- 2000-02-10 NO NO20000665A patent/NO314935B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
ZA987239B (en) | 2000-02-14 |
ATE525362T1 (de) | 2011-10-15 |
BG104122A (en) | 2000-11-30 |
EP1003728A1 (de) | 2000-05-31 |
BR9811177A (pt) | 2000-07-25 |
HUP0003710A2 (hu) | 2001-10-28 |
NO20000665D0 (no) | 2000-02-10 |
EP1003728B1 (de) | 2011-09-21 |
PL201927B1 (pl) | 2009-05-29 |
AU9342698A (en) | 1999-03-08 |
CO4960663A1 (es) | 2000-09-25 |
ID24639A (id) | 2000-07-27 |
AR016605A1 (es) | 2001-07-25 |
KR20010022833A (ko) | 2001-03-26 |
JP4444492B2 (ja) | 2010-03-31 |
DE19735410A1 (de) | 1999-02-18 |
CN1267286A (zh) | 2000-09-20 |
AU749575B2 (en) | 2002-06-27 |
SK1182000A3 (en) | 2000-09-12 |
NO314935B1 (no) | 2003-06-16 |
NZ502675A (en) | 2001-06-29 |
CA2301297A1 (en) | 1999-02-25 |
TR200000406T2 (tr) | 2000-05-22 |
EP2272833A1 (de) | 2011-01-12 |
WO1999009015A1 (de) | 1999-02-25 |
PL338603A1 (en) | 2000-11-06 |
NO20000665L (no) | 2000-02-10 |
JP2001515070A (ja) | 2001-09-18 |
IL134246A0 (en) | 2001-04-30 |
US20010020022A1 (en) | 2001-09-06 |
KR100571945B1 (ko) | 2006-04-18 |
ES2374156T3 (es) | 2012-02-14 |
IL134246A (en) | 2002-11-10 |
HUP0003710A3 (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101263116B (zh) | 可用作肝肉碱棕榈酰转移酶抑制剂的新型杂双环衍生物 | |
JP5134552B2 (ja) | ジヒドロプテリジノン誘導体の三塩酸塩形及び調製方法 | |
JP2008509953A (ja) | 4−[[(7r)−8−シクロペンチル−7−エチル−5,6,7,8−テトラヒドロ−5−メチル−4−6−オキソ−2−ピペリジニル]アミノ]−3−メトキシ−n−(1−メチル−4−ピペリジニル)ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用 | |
SI9520080A (sl) | Substituirane pirimidinske spojine in njihova uporaba | |
TW201215605A (en) | Manufacturing process for pyrimidine derivatives | |
HU228666B1 (en) | Stable polymorph of flibanserin and use thereof for preparing medicaments | |
CN104350047A (zh) | 作为钙敏感受体调节剂的取代苯并二氢吡喃化合物 | |
TW211008B (zh) | ||
JPH04308560A (ja) | ベンズアミドおよびスルホンアミド低血糖剤 | |
TW467912B (en) | 2-{3-[4-(2-T-Butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio}-4-pyrimidinol fumarate | |
TW408117B (en) | Use of N-substituted phenothiazines | |
TW454005B (en) | 4-indolylpiperazinyl derivatives | |
WO2002030896A1 (fr) | Derives 2,2-diphenylbutanamide et agents pharmaceutiques contenant ces composes | |
JPS58164577A (ja) | 4―ベンジル―1―(2h)イソキノロン誘導体 | |
JP3285421B2 (ja) | 2−アミノ−n−[[[4−(アミノカルボニル)ピリミジン−2−イル]アミノ]アルキル]ピリミジン−4−カルボキシアミド誘導体、その製造および医薬への応用 | |
US6486162B2 (en) | 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | |
JP4454314B2 (ja) | 4−(ジアリールメチル)−1−ピペラジニル誘導体 | |
KR880000729B1 (ko) | 아닐리노-1, 2, 3-트리아졸 유도체의 제조방법 | |
TW394768B (en) | Dithiolylidene acetamide derivatives and pharmaceutical compositions thereof for inhibiting the formation of advanced glycation end-products | |
US6346620B1 (en) | Methods for preparation of 2-(4-(4-(4,5-dichloro-2-methylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluoropyrimidine and salts thereof | |
JPH0625237A (ja) | 新規イミダゾール | |
MXPA00001161A (en) | 2-&lcub;3-[4-(2-T-BUTYL-6- TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL]PROPYLMERCAPTO&rcub;PYRIMIDIN-4-OL-FUMARATE | |
CZ2000450A3 (cs) | Sůl 2-[3-/4-(2-terc.-butyl-6-trifluormethyl-4- pyrimidinyl)-1-piperazinyl/propylthio]-4- pyrimidínolu s kyselinou fumarovou | |
JP2005530746A (ja) | カルベジロールファーマソルブ溶媒和物 | |
JPH07119197B2 (ja) | フェニルスルホニルアルキルカルボン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MM4A | Annulment or lapse of patent due to non-payment of fees |